QPPV.COM KNOWLEDGE ASSESSMENT

Ferric Carboxymaltose: Hypophosphataemia, Osteomalacia and Post-Marketing Risk

Test your understanding of the concepts covered by Ferric Carboxymaltose: Hypophosphataemia, Osteomalacia and Post-Marketing Risk.

Question 1 of 10Pass mark: 80%

Question 1 of 10 As of 3 October 2026, what was the regulatory status of the EU Article 31 review described in the article?

The European Commission had completed a class-wide decision The PRAC had issued a final recommendation that all products be withdrawn The review was ongoing, with no final PRAC recommendation, CMDh position or Commission decision implied The procedure had concluded that only oral iron products required monitoring

Question 2 of 10 How should expectedness be assessed for a report of osteomalacia after FCM?

Assume it is expected whenever hypophosphataemia appears anywhere in product information Use the reporter’s causal opinion as the sole reference Check the precise event wording against the applicable product-, jurisdiction- and time-specific reference safety information Treat every serious event in the same clinical area as unexpected

Question 3 of 10 How should chronic kidney disease be treated in the assessment of possible FCM-associated hypophosphataemia?

As proof that the phosphate change is unrelated to FCM As a factor that may modify phosphate handling, without assuming it eliminates clinically relevant risk As a reason to infer osteomalacia from any low phosphate result As a condition that makes serial phosphate results unnecessary

Question 4 of 10 A clinician stops FCM and phosphate later recovers. How should this dechallenge information be interpreted?

It can support temporal assessment but is not conclusive because recovery may occur for other reasons It proves that FCM was the only cause It confirms that osteomalacia was present It makes assessment of competing causes unnecessary

Question 5 of 10 Which conclusion about spontaneous-report data is most appropriate when assessing the FCM safety signal?

Report counts provide an incidence rate if the number of serious cases is known A rise in reports after a warning proves that the underlying event rate increased Reports can identify important cases but are affected by under-reporting, incomplete data, stimulated reporting and uncertain denominators Spontaneous reports should be disregarded whenever randomised trial data exist

Question 6 of 10 Which follow-up information is likely to be most useful for evaluating a suspected FCM-related phosphate case?

The patient’s preference for future iron treatment, without exposure dates or clinical results A general request for the complete medical record regardless of relevance Only whether the patient had anaemia before treatment Exact product, dose and dates; serial phosphate results; symptom course; diagnostic evidence; management and outcome

Question 7 of 10 Which sequence best describes the proposed mechanism linking ferric carboxymaltose (FCM) to hypophosphataemia?

FCM increases intact FGF23, promoting renal phosphate loss and reducing active vitamin D FCM suppresses FGF23, increasing urinary phosphate loss and reducing active vitamin D FCM directly blocks intestinal iron absorption, causing phosphate loss through the bowel FCM increases calcitriol, which suppresses renal phosphate reabsorption

Question 8 of 10 A pharmacovigilance team observes increasing reports after a safety communication. What is the most appropriate aggregate-level interpretation?

The underlying incidence must have increased by the same proportion The increase proves the communication was ineffective The increase establishes a formulation-wide causal effect The trend may reflect stimulated reporting as well as a change in occurrence and needs contextual assessment

Question 9 of 10 A patient has inflammatory bowel disease, vitamin D deficiency and recent FCM exposure. Which causality interpretation best reflects the article?

These factors may coexist, and FCM could precipitate or worsen phosphate depletion in a patient with reduced physiological reserve The comorbidities exclude any contribution from FCM FCM exposure proves that the comorbidities are irrelevant The combination is sufficient to diagnose osteomalacia without further assessment

Question 10 of 10 A valid report describes persistent weakness after FCM, but no phosphate result is available. What is the most appropriate handling?

Do not process the report until a laboratory result is obtained Process and report it as required, while documenting that phosphate was not measured or is unavailable and seeking proportionate follow-up Enter a normal phosphate result because none was reported Classify the event as confirmed hypophosphataemia based on the symptom

QPPV.com

Ferric Carboxymaltose: Hypophosphataemia, Osteomalacia and Post-Marketing Risk

Cookie Settings